SHERIDAN, WYOMING – May 6, 2025 – Boston Scientific Corporation (NYSE: BSX) has announced a major leadership transition, with Executive Vice President and Chief Financial Officer Dan Brennan set to retire after nearly three decades with the company. Brennan will step down from the CFO role at the end of June and continue serving as a senior advisor through early October 2025, as Jon Monson, currently Senior Vice President of Investor Relations, is appointed to succeed him.
Leadership Change Marks a Strategic Financial Milestone
This executive transition signifies a pivotal moment in Boston Scientific’s ongoing financial and operational evolution. Under Brennan’s financial stewardship since 2014, the company has achieved consistent, high-performance results while advancing its global footprint and innovation-driven strategy. His retirement marks the culmination of a career deeply embedded in strategic investments, cultural development, and enterprise growth.
“I thank Dan for his incredible leadership and tremendous contributions to Boston Scientific,” said Mike Mahoney, Chairman and Chief Executive Officer. “Dan has been a critical leader on our global team as we have transformed the trajectory of BSX financial performance over many years.”
Brennan’s tenure included:
- Oversight of numerous internal and external investment strategies.
- The cultivation of a strong, values-based finance organization.
- Pivotal leadership through multiple market cycles and macroeconomic challenges.
Jon Monson Brings Deep Financial Expertise to CFO Role
Jon Monson will formally assume the CFO position on June 30, 2025, reporting directly to Mahoney and joining the Executive Committee. The transition is designed to ensure operational continuity and strategic alignment across the company's finance verticals.
"Jon is a proven leader who is known for his strategic mindset, diligent and thoughtful leadership and focus on high performance and continuous innovation," Mahoney noted.
Monson’s appointment leverages more than 25 years of experience at Boston Scientific, with a robust background across key financial disciplines:
- Former Global Controller and Chief Accounting Officer.
- Vice President and Controller for the Urology business.
- A key financial strategist during the 2020 pandemic response.
As CFO, Monson will oversee:
- Global controllership and internal audit
- Corporate finance, treasury, and tax
- Investor relations and business development
- Talent development within the global finance organization
Continuity and Confidence in Boston Scientific’s Strategic Vision
The seamless CFO transition reinforces Boston Scientific’s commitment to long-term value creation and operational resilience. With a strong financial foundation and experienced leadership in place, the company remains well-positioned to advance its core mission: transforming lives through innovative medical technologies.
Boston Scientific continues to lead in medical device innovation with a broad portfolio addressing cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions. The leadership shift occurs at a time of strategic momentum, ensuring alignment with investor expectations and healthcare sector dynamics.
Learn more at www.bostonscientific.com